Denosumab, a fully humanized monoclonal neutralizing antibody, inhibits activation of the
RANK/RANKL/OPG signaling pathway through competitive binding with RANKL, thereby …

The clinical sequelae from bone metastases, termed skeletal-related events, are among the
most frequent and debilitating complications in patients with advanced cancer. Bone …

The clinical sequelae from bone metastases, termed skeletal-related events (SREs), are
among the most frequent and debilitating complications in patients with advanced cancer …

Background: Denosumab is fully human monoclonal antibody that specifically binds and
inactivates receptor activator of NF-kB ligand (RANKL), an important ligand that regulates …

The diagnosis of bone metastases is an event with certain consequences for the patient.
They often mean pain and can also mean pathological fractures, hypercalcemia, and spinal …

Denosumab is a fully human monoclonal antibody against RANK ligand (RANKL), an
essential cytokine for the formation, function, and survival of osteoclasts. The role of …

Introduction: The skeleton is generally the primary, and sometimes the only, site of
metastasis in patients with advanced solid tumors. Bone metastases are the most frequent …

Signalling of receptor activator of nuclear factor-κB (RANK) ligand (RANKL) through RANK
is a critical pathway to regulate the differentiation and activity of osteoclasts and, hence, a …

Skeletal-related events (SREs) including pain, fractures, and hypercalcemia are a major
source of morbidity for cancer patients with bone metastases. The receptor activator of NF …

Many patients with advanced cancer develop bone metastases, which reduces their quality
of life. Bone metastases are associated with an increased risk of skeletal-related events …